UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Position in Surgery Partners, Inc. $SGRY

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of Surgery Partners, Inc. (NASDAQ:SGRY) by 7.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,471,492 shares of the company’s stock after selling 117,876 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Surgery Partners were worth $24,721,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Jupiter Topco LLC bought a new stake in shares of Surgery Partners in the 2nd quarter worth approximately $233,220,000. Pentwater Capital Management LP bought a new position in Surgery Partners during the 2nd quarter valued at approximately $195,384,000. BlackRock Inc. bought a new position in Surgery Partners during the 2nd quarter valued at approximately $104,857,000. Hsbc Holdings PLC purchased a new position in Surgery Partners during the second quarter valued at $48,912,000. Finally, Goldman Sachs Group Inc. raised its stake in Surgery Partners by 528.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock valued at $30,277,000 after buying an additional 1,647,714 shares during the last quarter.

Surgery Partners Trading Up 1.4%

Shares of Surgery Partners stock opened at $14.17 on Friday. The company has a market capitalization of $1.86 billion, a P/E ratio of -20.24, a P/E/G ratio of 4.31 and a beta of 1.92. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.78 and a current ratio of 1.95. The company has a fifty day moving average of $15.43 and a 200 day moving average of $14.37. Surgery Partners, Inc. has a fifty-two week low of $11.41 and a fifty-two week high of $23.44.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Monday, August 10th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.04. Surgery Partners had a positive return on equity of 0.88% and a negative net margin of 2.63%.The business had revenue of $848.90 million for the quarter, compared to analysts’ expectations of $830.03 million. During the same period last year, the firm earned $0.17 earnings per share. The business’s quarterly revenue was up 2.7% on a year-over-year basis. On average, sell-side analysts anticipate that Surgery Partners, Inc. will post 0.22 earnings per share for the current fiscal year.

Insider Activity

In other Surgery Partners news, Director Teresa DeLuca bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were bought at an average price of $14.35 per share, with a total value of $143,500.00. Following the purchase, the director owned 66,843 shares of the company’s stock, valued at $959,197.05. This trade represents a 17.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SGRY. Zacks Research cut shares of Surgery Partners from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a report on Friday, August 21st. Royal Bank Of Canada decreased their target price on shares of Surgery Partners from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. TD Cowen increased their price target on shares of Surgery Partners from $17.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price target on shares of Surgery Partners in a report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Surgery Partners currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.45.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.